Clinical Trials

In the dynamic realm of oncology clinical trials, hope emerges as the driving force, lighting the way for patients in search of revolutionary treatments. Through these trials, the promise of tomorrow's treatments for Sarcoma patients  becomes the lifeline that inspires and empowers patients on their quest for healing. Below, you will find a table the summarizes the UpToDate Sarcoma Clinical Trials that are being investigated by the clinicians and scientists at our national sarcoma Consortium. 

CanSaRCC physicians and researchers from every center across the country have endorsed the concept of creating a platform which can track all sarcoma clinical trials. CanSaRCC has the power to provide ‘the denominator’ – that is, the landscape and prevalence of the different subtypes of  sarcoma across Canada. This initiative can help academic & clinical institutions, as well as pharma companies to  assess realistic trial feasibility, and identifying the ideal inclusive cohort of patients for novel drugs.

 

* For your convenience, please sort any column by clicking on the column header. 

* Please click on specific trial name for more information.

Status ▲PopulationTrial_NameDescriptionPhaseCentersPIIIST_Pharma
PENDINGMPNST, LMS, ESSPhase Ib of Metronomic Selinexor in MPNST, LMS and ESSMETSSAR-1 Ib/IIPMHA. RazakIIST
PENDINGAny soft tissue sarcoma undergoing surgery and radiationCirculating Tumor DNA in Soft Tissue SarcomaLiquid biopsy in early disease for soft tissue sarcomaProof of ConceptPMHA. Razak
D. Shultz
IIST
PENDINGPVNS/TGCTA Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell TumorEmactuzumab vs. placeboIIITBDA. RazakPharma
PENDINGVarious STS subtypesBRIGHTLINE-3MDM2i + CPI in selected sarcomas, TP53 WTIIITBDA. Razak 
PENDINGOsteosarcoma (AYA -residual OST (up to 30 yrs)CLIN-60000-461: A phase II, randomized, open-label study to assess the efficacy, safety, and pharmacokinetics (PK) of maintenance cabozantinib (XL184) plus best supportive care (BSC) versus BSC in children, adolescents and young adults (AYA) with unresectable residual osteosarcoma either at diagnosis or at first relapse after standard treatmentCabozantinib + best supportive care vs best supportive care onlyIITBDA. GuptaPharma
PENDINGAll sarcoma - initial consultEvaluating the Use of Educational Videos in a Medical Oncology Sarcoma Clinic to Improve Patient Knowledge and SatisfactionEarly intervention palliative care vs SOCPilotMSH and PMH onlyA. RazakIIST
RECRUITINGLocalized high risk sarcomaProspective Study of Hypoxia Imaging in Patients with Soft Tissue Sarcoma using Positron Emission Tomography (PET) with 18F-Fluoroazomycin Arabinoside (18F-FAZA) in combination with MRIFAZA for STS Proof of ConceptPMHD. ShultzIIST
RECRUITINGresectable LMS, LPSSR.7/1809-STBSG/STRASS-2. A Phase III Study of Neoadjuvant Chemotherapy Followed by Surgery versus Surgery Alone for Patients with High Risk Retroperitoneal SarcomaSurgery vs. Surgery plus Chemo IIIPMH
MSH
R. GladdyNCIC/EORTC
RECRUITINGRelapsed Osteosarcoma (1-35yrs)PED-CITN-03: Phase 1 Trial of Hu5F9-G4 (Magrolimab) Combined With Dinutuximab in Children and Young Adults With Relapsed and Refractory Neuroblastoma or Relapsed OsteosarcomaBiological: Dinutuximab, MagrolimabISickKids, BCCHD. Morgenstern, R. DeyellNCI
RECRUITINGEwing Sarcoma, Rhabdomyosarcoma, Osteosarcoma + other (2 -25yrs)DCL-17-001: An Open-Label, Dose Escalation, Efficacy, and Safety Study of CLR 131 in Children, Adolescents, and Young Adults With Select Solid Tumors, Lymphoma, and Malignant Brain TumorsDrug: CLR 131ISickKidsD. MorgensternPharma
RECRUITINGEwing Sarcoma, Rhabdomyosarcoma, other Solid Tumors (2-20yrs)ADVL1921: PHASE 1/2 STUDY TO EVALUATE PALBOCICLIB (IBRANCE(REGISTERED)) IN COMBINATION WITH IRINOTECAN AND TEMOZOLOMIDE AND/OR IN COMBINATION WITH TOPOTECAN AND CYCLOPHOSPHAMIDE IN PEDIATRIC PATIENTS WITH RECURRENT OR REFRACTORY SOLID TUMORSPalbociclib + chemoIISickKids
CHU Ste-Justine
D. Morgernstern
Y. Samson
COG + Pharma
RECRUITINGGIST(PEAK) A PHASE 3 RANDOMIZED, OPEN-LABEL, MULTICENTER CLINICAL STUDY OF CGT9486+SUNITINIB VS SUNITINIB IN SUBJECTS WITH LOCALLY ADVANCED, UNRESECTABLE OR METASTATIC GASTROINTESTINAL STROMAL TUMORSSunitinib +/- CGT9486IIIPMHA. RazakPharma
RECRUITINGGISTA Study of Ripretinib vs Sunitinib in Patients With Advanced GIST With Specific KIT Exon Mutations Who Were Previously Treated With Imatinib (INSIGHT)Ripretinib vs sunitinibIIIPMHA. RazakPharma
RECRUITINGLMSStudy of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)ADI-PEG 20 (arginine degrading enzyme) or Placebo Plus Gemcitabine and DocetaxelIIITBDA. RazakPharma
RECRUITINGChondrosarcomaA phase 3, multicenter, double blind, randomized, placebo-controlled study of ivosidenib in subjects ≥ 18 years of age with unresectable or metastatic conventional chondrosarcoma with an IDH1 mutation, untreated or previously treated with 1 prior systemic treatment regimenIvosidenib vs. placeboIIITBDA. SalawuPharma
RECRUITINGSynovial SarcomaSpearhead 1 Study in Subjects With Advanced Synovial Sarcoma or Myxoid/Round Cell LiposarcomaAdoptive cell therapy (ACT) in Synovial Sarcoma and m-LiposarcomaIIPMHA. RazakPharma
RECRUITINGRelapsed/Refractory Solid Tumours23ME-00610-CLIN-00123ME-00610 given by intravenous infusion I/IISickKidsD. MorgensternPharma
RECRUITINGAdvanced Solid Tumour/LGG, Age ≥12 yearsDAY101-102Tovorafenib, Tovorafenib plus pimasertib SickKidsD. MorgensternPharma
RECRUITINGRecurrent/Refractory Ewing Sarcoma, Hepatoblastoma, Neuroblastoma, Osteosarcoma, Rhabdoid Tumor, Rhabdomyosarcoma, Wilms, SarcomaONITT Onivyde With Talazoparib or TemozolomideISickKids, BCCHD. Morgenstern, R. DeyellIIST
RECRUITINGRelapsed or refractory Solid tumors, lymphoma, brain tumorsBMS BET 19-040investigational drug called BMS-986158 ISickKidsD. MorgensternIIST
RECRUITINGR/R solid tumor, including CNS tumors, with a mutation in PDGFRA and/or KIT. 2-18 yrsBLU-285-3101This is a Phase 1/2, multicenter, open-label trial of avapritinib, I/IISickKidsD. MorgensternPharma
RECRUITINGAdvanced and unresectable or metastatic solid malignancyBO41932 (TAPISTRY). unresectable, locally advanced or metastatic solid tumors determined to harbor specific oncogenic genomic alterations or who are tumor mutational burden (TMB)-high as identified by a validated next-generation sequencing (NGS) assayTargeted therapies or immunotherapy as single agents or in rational, specified combinations. IISickKidsD. MorgensternPharma
RECRUITING Advanced Solid TumorRP-6306 RP-6306 alone and in combination with RP-3500 ISickKidsD. MorgensternPharma
RECRUITINGDDLPS any lineBrightline-4: A Phase III Open-label, Single-arm, Multi-center Study to Assess the Safety and Efficacy of Brigimadlin (BI 907828) Treatment in Patients With Treatment-naïve or Pre-treated Advanced Dedifferentiated LiposarcomaMDM2iDrug access trialTBDA. RazakPharma
RECRUITINGAll sarcomaSARQUALITY: Integrating early palliative care in advanced SARcoma patients for enhanced QUALITY of life.Patient education videos vs SOCPilotMSH and PMH onlyA. RazakIIST
CLOSEDSynovial SarcomaMaster Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid TumorsACT in SS IIPMH
HMR
A. Razak
J. Noujaim
Pharma
CLOSEDLMSBasket Combination Study of Inhibitors of DNA Damage Response, Angiogenesis and Programmed Death Ligand 1 in Patients With Advanced Solid Tumors (DAPPER)DAPPER Study IIPMHL.Siu
A. Razak
IIST
CLOSEDExtremity/ trunk STSPhase III Study of Preoperative vs Postoperative Intensity Modulated Radiation Therapy For Truncal/Extremity Soft Tissue SarcomaPre vs Postop IMRT in extremity STS (50/50 study) IIIPMH
MSH
HMR
OHRI
DanaFarber
ClevalandClinic
OHSU
SaintLuc(Brussels)
P. ChungIIST
CLOSEDOsteosarcomaOLIEifosfamide and etoposide with or without Lenvatinib in children, adolescents and young adultsISickKidsD. MorgensternPharma
CLOSEDdd-Liposarcoma, at least 1 prior anthracycline-based regimenA Randomized Multicenter Phase 3 Study of Milademetan Versus Trabectedin in Patients with Dedifferentiated Liposarcoma (RAIN-3201)Milademetan vs trabectedin IIIPMHA. RazakPharma (***Patient Reimbursement)
CLOSEDDedifferentiated liposarcomaBrightline-1: A Phase II/III, randomized, open-label, multi-center study of BI 907828 compared to doxorubicin as first line treatment of patients with advanced dedifferentiated liposarcomaI 907828 vs doxorubicin as first line therapy in DDLPSII/IIIPMH, HMR, BCCA. Razak, J. Noujaim, A. SmrkePharma
CLOSEDHigh grade soft tissue sarcomaFAPi Radioligand OpeN-Label, Phase 1 Study to Evaluate Safety, Tolerability and DosImetry of [Lu-177]-PNT6555; A Dose Escalation Study for TReatment of Patients with Select Solid Tumors (FRONTIER)FAPi radioligand in high grade soft tissue sarcomaIPMHA. RazakPharma
CLOSEDLMS (fever than 4 lines of prior treatment)A Phase II/III Study to Evaluate the Efficacy and Safety of Unesbulin in Unresectable or Metastatic, Relapsed or Refractory Leiomyosarcoma (SUNRISE LMS)DTIC + unesbulin/placeboII/IIIPMHA. SalawuPharma
CLOSEDPVNS/TCGTA Phase 3, Randomized, Double-blind, Placebo-Controlled, Multicenter Study of ABSK021 to Assess the Efficacy and Safety in Patients With Tenosynovial Giant Cell TumorABSK021 (CSF-1R) vs. placebo IIITBDA. RazakPharma